argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
02 mai 2024 01h00 HE
|
argenx SE
May 2, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
16 avr. 2024 01h00 HE
|
argenx SE
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first...
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
27 mars 2024 02h00 HE
|
argenx SE
RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00...
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
26 mars 2024 16h00 HE
|
argenx SE
March 26, 2024 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
26 mars 2024 02h00 HE
|
argenx SE
VYVGART® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP) Regulatory decision in Japan represents first global approval for VYVGART in ITP ...
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
07 mars 2024 16h01 HE
|
argenx SE
ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years Abstracts reflect real-world value and consistent efficacy and safety profile associated with...
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
29 févr. 2024 01h00 HE
|
argenx SE
$374 million in fourth quarter and $1.2 billion in full year global net product sales sBLA for VYVGART® Hytrulo for CIDP accepted for priority review by FDA with PDUFA target action date of June...
argenx to Present at Upcoming Investor Conferences
26 févr. 2024 01h00 HE
|
argenx SE
February 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
22 févr. 2024 01h00 HE
|
argenx SE
February 22, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
20 févr. 2024 01h00 HE
|
argenx SE
Prescription Drug User Fee Act (PDUFA) target action date is June 21, 2024 If approved, VYVGART® Hytrulo will be the first neonatal Fc receptor (FcRn) blocker to treat CIDP February 20, 2024, 7:00...